Headlines

Santen Acquires Eyevance in $225M Deal

Osaka-based Santen has acquired Fort Worth, TX-based Eyevance, which develops topical ophthalmic products, for $225 million.

“We’re very pleased to have entered into this agreement,” said Shigeo Taniuchi, Santen president and CEO. “Through this purchase, we will quickly establish a business base in the U.S. and both humbly face and further contribute to the needs of a greater number of patients by offering more value. At the same time, we will accelerate global business rollout by gaining access to the U.S. and our presence in the market, aiming for even further corporate growth and contribution to ophthalmic treatments for people around the world.”

Photo Gallery

INVISION Races to Miami with Ferrari and Ray-Ban

Photo Gallery

11 Images That Show Why The Novel Eye in North Kingstown Was Named One of America’s Finest Optical Retailers for 2023-24

Photo Gallery

11 Images That Show Why Respect Eyecare in Calgary Was Named One of (North) America’s Finest Optical Retailers

Santen Holdings U.S. Inc. bought all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. Eyevance is now a wholly owned subsidiary of Santen. Visovanq (sterile vancomycin ophthalmic ointment) and Nexagon (ophthalmic gel for persistent corneal epithelial defects), both of which were being developed by Eyevance, were carved out of the transaction with Santen and are excluded from the purchase.

Founded in 2017, Eyevance has developed and commercialized topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, anti-fungal, anti-infective/anti-inflammatory fixed combination, and tear lubricant products. Eyevance’s current commercialization strategy is supported by a national sales team exclusively targeting ophthalmologists, optometrists and allergists throughout the U.S.

“Eyevance is proud of its accomplishments over the past three years and looks forward to joining Santen, one of the leading ophthalmic companies worldwide, with its innovative R&D expertise and legacy of global success,” said co-founders Jerry St. Peter, CEO and director, and Jason Werner, COO, Eyevance Pharmaceuticals LLC, in a press release. “We are excited to become part of Santen’s U.S. organization, to work in collaboration to further strengthen the existing commercial business. As Eyevance embarks on this new journey with Santen, we sincerely appreciate the Eyevance Team and its shareholders for their unwavering support and continuous pursuit of excellence.”

INVISION Staff

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Recent Posts

How Small Eyecare Businesses Can Afford Medical Benefits for Employees

It's about finding the right fit between valuable employee benefits and what's financially feasible for…

7 hours ago

Medical Advice Gone Wrong

Apparently, when providing treatment plans you must be very, very explicit…

7 hours ago

The Bottom Line: How to Stand Out When Hiring

Recruiting associate optometrists is vital to practice growth but with a shortage of ODs in…

7 hours ago

More Contact Lens Adoption Could Be as Easy as Talking About It and More of What You Need to Know for May

Plus the economic impact of better vision and enhanced online staff training resources.

8 hours ago

An Ultrasonic Cleaner for at Home Use and More Business Boosters for May

Plus labels, stickers and creepy little bling you can’t help but love.

8 hours ago

Your Letters to the Editor For May

"INVISION helped inspire me to become an independent. You have wonderful content. It is the…

9 hours ago

This website uses cookies.